Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AES 2022 | Cenobamate therapy reduces concomitant drug load in patients with epilepsy

William E. Rosenfeld, MD, The Comprehensive Epilepsy Care Center for Children and Adults, St Louis, MO, discusses the impact of adjunctive cenobamate use on concomitant drug load. A recent post-hoc analysis of the Phase III C021 safety study (NCT02535091) showed that total concomitant antiseizure medication (ASM) drug load decreased following cenobamate initiation in all patient subsets and for all ASM drug classes. Patients with no change in concomitant drug load versus low, moderate, or high reduction all had similar maintenance of ≥ 50% and 100% response rates. Additionally, a retrospective chart review of 79 patients receiving cenobamate in a real-world setting showed more than half of patients to have a reduction in concomitant ASM drug load. Monotherapy with cenobamate was achieved in 9 patients, with a further 12 in the process of tapering off other medications. Overall, these findings suggest that cenobamate may allow a reduction or elimination of polytherapy in some patients, positively impacting the rates of treatment emergent adverse events. This interview took place at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, TN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultant/advisor: Arvelle, SK Life Science, Inc.; Speaker: SK Life Science, Inc.; Research Support: SK Life Science, Inc., UCB Pharma.